vTv Therapeutics

Historical price data

vTv Therapeutics is a clinical-stage biotech focused on developing oral small-molecule drugs for chronic diseases, with its entire strategy anchored on cadisegliatin, a liver-selective glucokinase activator for Type 1 Diabetes (T1D). The company's mission is to address the significant unmet need in T1D by providing an oral adjunct to insulin that improves glycemic control without increasing hypoglycemia risk. Its achievement rests on advancing this novel mechanism into a pivotal Phase 3 trial (Simplici-T1), with the strategic goal of securing regulatory approval and capturing a first-mover advantage in a large, underserved market. vTv's future is intrinsically tied to the success or failure of this single, late-stage asset.

Liver-selective glucokinase (GK) activation platform for oral small-molecule therapies designed to modulate hepatic glucose metabolism without stimulating pancreatic insulin secretion.

Cadisegliatin's primary competition is from SGLT2 inhibitors investigated for T1D, which carry a DKA risk, and advancing diabetes technology which it aims to complement. Its key competitive advantage is its first-in-class, oral, liver-selective mechanism designed to avoid both hypoglycemia and DKA, positioning it uniquely in a sparse market.